CN107406414B - 作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物 - Google Patents
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物 Download PDFInfo
- Publication number
- CN107406414B CN107406414B CN201680014364.2A CN201680014364A CN107406414B CN 107406414 B CN107406414 B CN 107406414B CN 201680014364 A CN201680014364 A CN 201680014364A CN 107406414 B CN107406414 B CN 107406414B
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- alkyl
- piperidin
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101927P | 2015-01-09 | 2015-01-09 | |
| US62/101,927 | 2015-01-09 | ||
| PCT/US2016/012638 WO2016112284A1 (en) | 2015-01-09 | 2016-01-08 | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107406414A CN107406414A (zh) | 2017-11-28 |
| CN107406414B true CN107406414B (zh) | 2022-04-19 |
Family
ID=55299746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680014364.2A Expired - Fee Related CN107406414B (zh) | 2015-01-09 | 2016-01-08 | 作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10280149B2 (enExample) |
| EP (1) | EP3242872B1 (enExample) |
| JP (1) | JP6855379B2 (enExample) |
| CN (1) | CN107406414B (enExample) |
| WO (1) | WO2016112284A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7788208B2 (ja) * | 2017-03-29 | 2025-12-18 | パデュー リサーチ ファウンデイション | キナーゼネットワークの阻害剤およびその使用 |
| MA52005A (fr) * | 2018-03-14 | 2021-01-20 | Prelude Therapeutics Inc | Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) |
| EP4149917B1 (en) * | 2020-05-12 | 2025-07-30 | Merck Sharp & Dohme LLC | Factor xi activation inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007059323A3 (en) * | 2005-11-15 | 2007-12-27 | Cytokinetics Inc | Certain chemical entities, compositions, and methods |
| WO2013123411A1 (en) * | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
| WO2014151106A1 (en) * | 2013-03-15 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| LU77659A1 (de) * | 1977-06-30 | 1979-03-26 | Byk Gulden Lomberg Chem Fab | Piperidinoadamantane,verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| EP0836605B1 (en) | 1995-07-06 | 2002-02-06 | Novartis AG | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| NZ503991A (en) | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
| CA2389049A1 (en) * | 1999-09-27 | 2001-04-05 | Georgetown University | Dopamine transporter inhibitors and their use |
| US8541572B2 (en) * | 2008-11-10 | 2013-09-24 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| WO2012071469A2 (en) * | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
-
2016
- 2016-01-08 WO PCT/US2016/012638 patent/WO2016112284A1/en not_active Ceased
- 2016-01-08 EP EP16702830.7A patent/EP3242872B1/en active Active
- 2016-01-08 JP JP2017536302A patent/JP6855379B2/ja not_active Expired - Fee Related
- 2016-01-08 CN CN201680014364.2A patent/CN107406414B/zh not_active Expired - Fee Related
-
2017
- 2017-07-07 US US15/643,808 patent/US10280149B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007059323A3 (en) * | 2005-11-15 | 2007-12-27 | Cytokinetics Inc | Certain chemical entities, compositions, and methods |
| WO2013123411A1 (en) * | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
| WO2014151106A1 (en) * | 2013-03-15 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
Non-Patent Citations (7)
| Title |
|---|
| 4-(β-Arylvinyl)-3-(β-arylvinylketo)-1-ethyl-4-piperidinols and Related Compounds: A Novel Class of Cytotoxic and Anticancer Agents;Jonathan R. Dimmock, et al.;《J.Med.Chem.》;19980919;第41卷;Scheme 1 * |
| Conformationally-restricted Ligands for the Histamine H1 Receptor;Christopher Upton, et al.;《Bioorganic & Medicinal Chemistry Letters》;20001231;第10卷;Scheme1 * |
| Exploration of Piperidinols as Potential Antitubercular Agents;Areej Abuhammad et al.;《Molecules》;20141010;第19卷;表1 * |
| Identification of small-molecule inhibitors of Trypansoma cruzi replication;Andrew R. Germain et al.;《Bioorganic & Medicinal Chemistry Letters》;20110929;第21卷;表3 * |
| KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state;David Frescas et al.;《Cell Cycle》;20081115;第7卷(第22期);全文 * |
| REGISTRY;REGISTRY;《STN》;20081102;全文 * |
| The β2-Adrenoceptor Agonist Formoterol Stimulates Mitochondrial Biogenesis;Lauren P. Wills, et al.;《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》;20121231;第342卷(第1期);表2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3242872B1 (en) | 2019-07-03 |
| US10280149B2 (en) | 2019-05-07 |
| CN107406414A (zh) | 2017-11-28 |
| JP2018501288A (ja) | 2018-01-18 |
| EP3242872A1 (en) | 2017-11-15 |
| WO2016112284A1 (en) | 2016-07-14 |
| HK1247198A1 (zh) | 2018-09-21 |
| JP6855379B2 (ja) | 2021-04-07 |
| US20180022727A1 (en) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107912040B (zh) | 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物 | |
| JP6847844B2 (ja) | 治療用ピリダジン化合物およびその使用 | |
| CN109476663B (zh) | 用于治疗癌症的吡唑并吡啶衍生物 | |
| CN109476641B (zh) | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 | |
| CN107108512B (zh) | 治疗性化合物及其用途 | |
| CN105980386B (zh) | 吡唑并化合物及其用途 | |
| CN107531690B (zh) | 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物 | |
| CN101321756A (zh) | 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物 | |
| CN101360499A (zh) | 吡唑并[1,5-a]嘧啶衍生物在抑制蛋白激酶的方法中抑制蛋白激酶的用途 | |
| JP6816105B2 (ja) | ブロモドメイン阻害剤としてのベンゾジアゼピン | |
| US10280149B2 (en) | Therapeutic compounds and uses thereof | |
| CN107406418B (zh) | 4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途 | |
| HK1247198B (en) | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives as inhibitors of the histone demethylase kdm2b for the treatment of cancer | |
| HK40079501A (en) | Heterocyclic inhibitors of cbp/ep300 and their use in treatment of cancer | |
| HK40005958A (en) | Pyrazolopyridine derivatives for the treatment of cancer | |
| HK40005957B (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| HK40005957A (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| HK1247194A1 (en) | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors | |
| HK1248696B (zh) | 治療性噠嗪化合物及其用途 | |
| HK1248695B (zh) | 用作cbp和/或ep300抑制劑的4，5，6，7-四氫-1h-吡唑並[4，3-c]吡啶-3-胺化合物 | |
| HK40005958B (zh) | 用於治疗癌症的吡唑并吡啶衍生物 | |
| HK1226056B (zh) | 吡唑並化合物及其用途 | |
| HK1253559B (zh) | 作為組蛋白脫甲基酶抑制劑的吡咯烷酰胺化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1247198 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TG01 | Patent term adjustment | ||
| TG01 | Patent term adjustment |
Free format text: NEW EXPIRY DATE: 20360216 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220419 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |